Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 for megakaryocytic engraftment after allo-HSCT in bone marrow failure diseases
ChiCTR2600116641Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jan 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of romiplostim in aplastic anemia, myelodysplastic syndrome (MDS), myelofibrosis (MF) and 1 more, sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Platelet implantation rate. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
aplastic anemiamyelodysplastic syndrome (MDS)myelofibrosis (MF)bone marrow failure
Beyond the preview
Go deeper on ChiCTR2600116641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116641.